Pages that link to "Q36739807"

The following pages link to The evolving role of lenalidomide in the treatment of hematologic malignancies (Q36739807):

Displaying 18 items.

• Current and emerging treatment options for patients with relapsed myeloma (Q26830878) (← links)
• Immunomodulatory agents in myelofibrosis (Q33401615) (← links)
• Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (Q33973877) (← links)
• Pathogenesis and treatment of renal failure in multiple myeloma (Q34592826) (← links)
• Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma (Q34611491) (← links)
• Expanding role of lenalidomide in hematologic malignancies (Q35592305) (← links)
• A Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules (Q36960501) (← links)
• Novel anti-myeloma agents and angiogenesis. (Q37132903) (← links)
• Lenalidomide and its role in the management of multiple myeloma (Q37183439) (← links)
• Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice (Q37991783) (← links)
• Choosing treatment options for patients with relapsed/refractory multiple myeloma (Q38170453) (← links)
• Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma (Q39305248) (← links)
• Distribution of lenalidomide into semen of healthy men after multiple oral doses (Q43160182) (← links)
• Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease (Q43246032) (← links)
• Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases (Q43447911) (← links)
• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (Q43726973) (← links)
• Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? (Q46859906) (← links)
• Pain Management in Patients with Multiple Myeloma: An Update (Q92151855) (← links)